US Drug Recall Register
Class II · Moderate risk Terminated Initiated Mar 9, 2023 (3 years ago)

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mix-up

What was recalled

JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA

Recalling firm
Boehringer Ingelheim Pharmaceuticals, Inc.
NDC code
0597-0153-30
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0468-2023

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Empagliflozin recalls

See all